BioCryst Pharmaceuticals announces NIAID contract for Marburg vaccine
The NIAID, a subsidiary of the National Institutes of Health, gave an initial award of $5 million to BioCryst to begin the development of BCX4430. The contract may be worth up to $22.0 million over the course of five years if all contract options are used.
The contract will support the development of BCX4430 into intravenous and intramuscular applications against the Marburg virus disease. The contract also supports the Phase 1 human clinical trial.
BioCryst offers a line of broad-spectrum antiviral drugs. BCX4430 is the leading drug offered by the company's BSAV program.
"Filovirus diseases such as Marburg virus hemorrhagic fever represent serious threats to national security, and the U.S. Government has prioritized the development of medical countermeasures against these diseases," BioCryst Chief Medical Officer Dr. William P. Sheridan said. "We are very pleased that NIAID has selected BioCryst's BCX4430 BSAV program as an early development project in this important field."
The project will be funded through federal funds from the National Institutes of Health, Department of Health and Human Services and National Institute of Allergy and Infectious Diseases.